<DOC>
	<DOCNO>NCT01351688</DOCNO>
	<brief_summary>The primary aim study gain initial assessment safety tolerability AZD3514 Japanese patient together assess Pharmacokinetics ( PK ) gain preliminary assessment anti-tumour action . In study , AZD3514 administer Japanese patient metastatic castration resistant prostate cancer .</brief_summary>
	<brief_title>An Open Label Prostate Cancer Study Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males age 20 year old . Histologically Cytologically proven diagnosis prostate cancer standard therapy currently consider appropriate Documented evidence metastatic prostate cancer Serum testosterone concentration â‰¤50 ng/dL World Health Organisation ( WHO ) performance status 0 1 deterioration previous 2 week minimum life expectancy 12 week History hypersensitivity active inactive excipients AZD3514 drug similar chemical structure class AZD3514 Refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection would preclude adequate absorption AZD3514 Inadequate bone marrow reserve organ function Concurrent recent treatment certain medication medical procedure Any medically important factor identify electrocardiogram ( ECG ) measurement</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castration resistant</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Androgen receptor</keyword>
	<keyword>Down regulation</keyword>
	<keyword>Japanese</keyword>
</DOC>